Olink Holding AB
2024
$3.1B
Outcome
Integrated into Specialty Diagnostics and Life Sciences, enabling researchers to analyze thousands of proteins simultaneously for precision healthcare.
Thermo Fisher Scientific Inc.
Life Sciences ToolsFounded 1956- HQ today: Waltham, Massachusetts, United States
Reviewed by Swet Parvadiya
Company data updated: October 2026
Acquisitions
Thermo Fisher Scientific Acquisitions
4
Major Deals Covered
$41.3B
Disclosed Deal Value
What are Thermo Fisher Scientific's biggest acquisitions?
Thermo Fisher Scientific's largest disclosed acquisition here is PPD, Inc. for $17.4 in 2021. This page covers 4 major deals from 2014 to 2024, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- PPD, Inc. ($17.4)
- First deal
- 2014
- Most recent
- 2024
| Company | Year | Price | Purpose |
|---|---|---|---|
| Life Technologies Corporation | 2014 | Undisclosed | — |
| Patheon N.V. | 2017 | Undisclosed | — |
| PPD, Inc. | 2021 | Undisclosed | — |
| Olink Holding AB | 2024 | Undisclosed | — |
- What companies has Thermo Fisher Scientific bought?
- Major acquisitions by Thermo Fisher Scientific documented here include PPD, Inc. (2021), Life Technologies Corporation (2014), Patheon N.V. (2017) and Olink Holding AB (2024).
- What is Thermo Fisher Scientific's most recent acquisition?
- The most recent Thermo Fisher Scientific acquisition documented here is Olink Holding AB, in 2024, for $3.1.
PPD, Inc.
2021
$17.4B
Outcome
Integrated into Laboratory Products and Biopharma Services, providing comprehensive clinical development solutions to global biotech and pharma clients.
Patheon N.V.
2017
$7.2B
Outcome
Expanded into the Pharma Services segment, enabling pharmaceutical partners to outsource complex biologic and small-molecule drug manufacturing.
Life Technologies Corporation
2014
$13.6B
Outcome
Fully integrated into Life Sciences Solutions, driving accelerated biopharma R&D and precision medicine advancements worldwide.
Thermo Fisher Scientific Inc.'s Growth & Acquisition Strategy
Expanding Patheon CDMO and PPD clinical trial capacity, scaling high-margin precision proteomics (Olink), deepening digital laboratory informatics, and capturing secular biopharma outsourcing demand.
How Thermo Fisher Scientific Inc. Makes Money
Thermo Fisher operates a high-moat recurring revenue model across four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Over 60% of revenue comes from recurring consumables, reagents, and services.
Thermo Fisher Scientific Acquisitions FAQ
What is Thermo Fisher Scientific's general approach to M&A and acquisitions?
Thermo Fisher Scientific pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by Thermo Fisher Scientific?
Transformative transactions in Thermo Fisher Scientific's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does Thermo Fisher Scientific successfully integrate acquired companies?
Thermo Fisher Scientific deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does Thermo Fisher Scientific divest non-core corporate assets?
Yes, Thermo Fisher Scientific periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Thermo Fisher Scientific
Core profile pages, founders and related research hubs for this company.